The interplay of reactive oxygen species and the epidermal growth factor receptor in tumor progression and drug resistance

Meng Shih Weng, Jer Hwa Chang, Wen Yueh Hung, Yi Chieh Yang, Ming Hsien Chien

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Background: The epidermal growth factor receptor (EGFR) plays important roles in cell survival, growth, differentiation, and tumorigenesis. Dysregulation of the EGFR is a common mechanism in cancer progression especially in non-small cell lung cancer (NSCLC). Main body: Suppression of the EGFR-mediated signaling pathway is used in cancer treatment. Furthermore, reactive oxygen species (ROS)-induced oxidative stress from mitochondrial dysfunction or NADPH oxidase (NOX) overactivation and ectopic expression of antioxidative enzymes were also indicated to be involved in EGFR-mediated tumor progression (proliferation, differentiation, migration, and invasion) and drug resistance (EGFR tyrosine kinase inhibitor (TKI)). The products of NOX, superoxide and hydrogen peroxide, are considered to be major types of ROS. ROS are not only toxic materials to cells but also signaling regulators of tumor progression. Oxidation of both the EGFR and downstream phosphatases by ROS enhances EGFR-mediated signaling and promotes tumor progression. This review primarily focuses on the recent literature with respect to the roles of the EGFR and ROS and correlations between ROS and the EGFR in tumor progression and EGFR TKI resistance. Short conclusion: The evidence discussed in this article can serve as a basis for basic and clinical research to understand how to modulate ROS levels to control the development and drug resistance of cancers.

Original languageEnglish
Article number61
JournalJournal of Experimental and Clinical Cancer Research
Volume37
Issue number1
DOIs
Publication statusPublished - Mar 16 2018

Fingerprint

Epidermal Growth Factor Receptor
Drug Resistance
Reactive Oxygen Species
Neoplasms
NADPH Oxidase
Protein-Tyrosine Kinases
Poisons
Phosphoric Monoester Hydrolases
Non-Small Cell Lung Carcinoma
Superoxides
Hydrogen Peroxide
Cell Survival
Carcinogenesis
Oxidative Stress
Enzymes
Growth
Research

Keywords

  • Drug resistance
  • Epidermal growth factor receptor
  • NADPH oxidase
  • Oxidation
  • Reactive oxygen species
  • Tumor progression

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The interplay of reactive oxygen species and the epidermal growth factor receptor in tumor progression and drug resistance. / Weng, Meng Shih; Chang, Jer Hwa; Hung, Wen Yueh; Yang, Yi Chieh; Chien, Ming Hsien.

In: Journal of Experimental and Clinical Cancer Research, Vol. 37, No. 1, 61, 16.03.2018.

Research output: Contribution to journalReview article

@article{600b1a56087149ce9fb1045899eec854,
title = "The interplay of reactive oxygen species and the epidermal growth factor receptor in tumor progression and drug resistance",
abstract = "Background: The epidermal growth factor receptor (EGFR) plays important roles in cell survival, growth, differentiation, and tumorigenesis. Dysregulation of the EGFR is a common mechanism in cancer progression especially in non-small cell lung cancer (NSCLC). Main body: Suppression of the EGFR-mediated signaling pathway is used in cancer treatment. Furthermore, reactive oxygen species (ROS)-induced oxidative stress from mitochondrial dysfunction or NADPH oxidase (NOX) overactivation and ectopic expression of antioxidative enzymes were also indicated to be involved in EGFR-mediated tumor progression (proliferation, differentiation, migration, and invasion) and drug resistance (EGFR tyrosine kinase inhibitor (TKI)). The products of NOX, superoxide and hydrogen peroxide, are considered to be major types of ROS. ROS are not only toxic materials to cells but also signaling regulators of tumor progression. Oxidation of both the EGFR and downstream phosphatases by ROS enhances EGFR-mediated signaling and promotes tumor progression. This review primarily focuses on the recent literature with respect to the roles of the EGFR and ROS and correlations between ROS and the EGFR in tumor progression and EGFR TKI resistance. Short conclusion: The evidence discussed in this article can serve as a basis for basic and clinical research to understand how to modulate ROS levels to control the development and drug resistance of cancers.",
keywords = "Drug resistance, Epidermal growth factor receptor, NADPH oxidase, Oxidation, Reactive oxygen species, Tumor progression",
author = "Weng, {Meng Shih} and Chang, {Jer Hwa} and Hung, {Wen Yueh} and Yang, {Yi Chieh} and Chien, {Ming Hsien}",
year = "2018",
month = "3",
day = "16",
doi = "10.1186/s13046-018-0728-0",
language = "English",
volume = "37",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The interplay of reactive oxygen species and the epidermal growth factor receptor in tumor progression and drug resistance

AU - Weng, Meng Shih

AU - Chang, Jer Hwa

AU - Hung, Wen Yueh

AU - Yang, Yi Chieh

AU - Chien, Ming Hsien

PY - 2018/3/16

Y1 - 2018/3/16

N2 - Background: The epidermal growth factor receptor (EGFR) plays important roles in cell survival, growth, differentiation, and tumorigenesis. Dysregulation of the EGFR is a common mechanism in cancer progression especially in non-small cell lung cancer (NSCLC). Main body: Suppression of the EGFR-mediated signaling pathway is used in cancer treatment. Furthermore, reactive oxygen species (ROS)-induced oxidative stress from mitochondrial dysfunction or NADPH oxidase (NOX) overactivation and ectopic expression of antioxidative enzymes were also indicated to be involved in EGFR-mediated tumor progression (proliferation, differentiation, migration, and invasion) and drug resistance (EGFR tyrosine kinase inhibitor (TKI)). The products of NOX, superoxide and hydrogen peroxide, are considered to be major types of ROS. ROS are not only toxic materials to cells but also signaling regulators of tumor progression. Oxidation of both the EGFR and downstream phosphatases by ROS enhances EGFR-mediated signaling and promotes tumor progression. This review primarily focuses on the recent literature with respect to the roles of the EGFR and ROS and correlations between ROS and the EGFR in tumor progression and EGFR TKI resistance. Short conclusion: The evidence discussed in this article can serve as a basis for basic and clinical research to understand how to modulate ROS levels to control the development and drug resistance of cancers.

AB - Background: The epidermal growth factor receptor (EGFR) plays important roles in cell survival, growth, differentiation, and tumorigenesis. Dysregulation of the EGFR is a common mechanism in cancer progression especially in non-small cell lung cancer (NSCLC). Main body: Suppression of the EGFR-mediated signaling pathway is used in cancer treatment. Furthermore, reactive oxygen species (ROS)-induced oxidative stress from mitochondrial dysfunction or NADPH oxidase (NOX) overactivation and ectopic expression of antioxidative enzymes were also indicated to be involved in EGFR-mediated tumor progression (proliferation, differentiation, migration, and invasion) and drug resistance (EGFR tyrosine kinase inhibitor (TKI)). The products of NOX, superoxide and hydrogen peroxide, are considered to be major types of ROS. ROS are not only toxic materials to cells but also signaling regulators of tumor progression. Oxidation of both the EGFR and downstream phosphatases by ROS enhances EGFR-mediated signaling and promotes tumor progression. This review primarily focuses on the recent literature with respect to the roles of the EGFR and ROS and correlations between ROS and the EGFR in tumor progression and EGFR TKI resistance. Short conclusion: The evidence discussed in this article can serve as a basis for basic and clinical research to understand how to modulate ROS levels to control the development and drug resistance of cancers.

KW - Drug resistance

KW - Epidermal growth factor receptor

KW - NADPH oxidase

KW - Oxidation

KW - Reactive oxygen species

KW - Tumor progression

UR - http://www.scopus.com/inward/record.url?scp=85044006289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044006289&partnerID=8YFLogxK

U2 - 10.1186/s13046-018-0728-0

DO - 10.1186/s13046-018-0728-0

M3 - Review article

AN - SCOPUS:85044006289

VL - 37

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 1

M1 - 61

ER -